Flexion extends a new grant opportunity by way of a Request for Proposal/RFP focused on research trials that seek to further understand specific areas within the osteoarthritis therapeutic area. These programs represent Flexion’s commitment to address unmet patient needs within the musculoskeletal therapeutic area and include innovating methods for screening, diagnosis and access, opioid-sparing techniques, addressing gaps in care for specific populations, and understanding disease epidemiology and patient-reported outcomes.
To be eligible for consideration, the requestor must be an independent third party. Examples of appropriate requestors include, but are not limited to HCPs and researchers affiliated with:
- Academic medical centers
- Healthcare institutions
- Private practice settings
- Ambulatory care facilities
Note: If the research involves multiple departments within an institution and/or practice, please note each department’s role in the RFP grant application.
Focus Areas Currently Accepting Letters of Intent:
- Forgotten Joint Score
- Impact of TA-ER treatment of Knee OA in the Background of Rheumatologic Diseases With High Disease Burden
- Opioid-Sparing Approaches in the Management of Knee Osteoarthritis Pain
- Tools to Characterize the Stiffness Component of Knee OA
- Treating Knee Osteoarthritis With TA-ER in People With Type 2 Diabetes Mellitus
- Understanding the Effects of Healthcare Disparities on OA Symptomatology, Disease Progression, and Treatment Response
Your proposal will be considered by Flexion’s cross-functional research committee that meets routinely to review RFP proposals. Flexion may make suggestions to improve the scientific merit of the proposal and enhance consistency with Flexion’s support approval criteria described above, although as the study sponsor, the principal investigator will have full and final discretion and responsibility for all aspects of the study design, implementation, data analysis, and data dissemination, including compliance with all laws and regulations applicable to research sponsors. The terms under which Flexion will provide support must be contained in a written agreement. Flexion provides no guarantees that the research committee will provide support for your proposal.
To submit a response to a Request for Proposal, please click here to navigate to our new RFP Inquiry Page.
For questions related to submission of your Request for Proposal, please contact your Regional Medical Scientific Director (RMSD) or email RFPcoordinator@flexiontherapeutics.com.
Indication and Select Important Safety Information
Indication: ZILRETTA is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.
Limitation of Use: The efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.
Contraindication: ZILRETTA is contraindicated in patients who are hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product.
Warnings and Precautions:
Intra-articular Use Only: ZILRETTA has not been evaluated and should not be administered by epidural, intrathecal, intravenous, intraocular, intramuscular, intradermal, or subcutaneous routes. ZILRETTA should not be considered safe for epidural or intrathecal administration.
Serious Neurologic Adverse Reactions with Epidural and Intrathecal Administration: Serious neurologic events have been reported following epidural or intrathecal corticosteroid administration. Corticosteroids are not approved for this use.
Hypersensitivity reactions: Serious reactions have been reported with triamcinolone acetonide injection. Institute appropriate care if an anaphylactic reaction occurs.
Joint infection and damage: A marked increase in joint pain, joint swelling, restricted motion, fever and malaise may suggest septic arthritis. If this occurs, conduct appropriate evaluation and if confirmed, institute appropriate antimicrobial treatment.
Other warnings and precautions for ZILRETTA and corticosteroids as a class include, alterations in endocrine function, cardiovascular and renal effects, increased intraocular pressure, GI perforation, alterations in bone density and behavior and mood disturbances.